These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

767 related articles for article (PubMed ID: 28266091)

  • 1. Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer.
    Hida T; Nishio M; Nogami N; Ohe Y; Nokihara H; Sakai H; Satouchi M; Nakagawa K; Takenoyama M; Isobe H; Fujita S; Tanaka H; Minato K; Takahashi T; Maemondo M; Takeda K; Saka H; Goto K; Atagi S; Hirashima T; Sumiyoshi N; Tamura T
    Cancer Sci; 2017 May; 108(5):1000-1006. PubMed ID: 28266091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer.
    Nishio M; Hida T; Atagi S; Sakai H; Nakagawa K; Takahashi T; Nogami N; Saka H; Takenoyama M; Maemondo M; Ohe Y; Nokihara H; Hirashima T; Tanaka H; Fujita S; Takeda K; Goto K; Satouchi M; Isobe H; Minato K; Sumiyoshi N; Tamura T
    ESMO Open; 2016; 1(4):e000108. PubMed ID: 28861280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy.
    Lee JS; Lee KH; Cho EK; Kim DW; Kim SW; Kim JH; Cho BC; Kang JH; Han JY; Min YJ; Park K
    Lung Cancer; 2018 Aug; 122():234-242. PubMed ID: 30032838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
    Rizvi NA; Mazières J; Planchard D; Stinchcombe TE; Dy GK; Antonia SJ; Horn L; Lena H; Minenza E; Mennecier B; Otterson GA; Campos LT; Gandara DR; Levy BP; Nair SG; Zalcman G; Wolf J; Souquet PJ; Baldini E; Cappuzzo F; Chouaid C; Dowlati A; Sanborn R; Lopez-Chavez A; Grohe C; Huber RM; Harbison CT; Baudelet C; Lestini BJ; Ramalingam SS
    Lancet Oncol; 2015 Mar; 16(3):257-65. PubMed ID: 25704439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study.
    Yamazaki N; Kiyohara Y; Uhara H; Uehara J; Fujimoto M; Takenouchi T; Otsuka M; Uchi H; Ihn H; Minami H
    Cancer Sci; 2017 Jun; 108(6):1223-1230. PubMed ID: 28342215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
    Gettinger S; Rizvi NA; Chow LQ; Borghaei H; Brahmer J; Ready N; Gerber DE; Shepherd FA; Antonia S; Goldman JW; Juergens RA; Laurie SA; Nathan FE; Shen Y; Harbison CT; Hellmann MD
    J Clin Oncol; 2016 Sep; 34(25):2980-7. PubMed ID: 27354485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer.
    Kato T; Masuda N; Nakanishi Y; Takahashi M; Hida T; Sakai H; Atagi S; Fujita S; Tanaka H; Takeda K; Satouchi M; Namba Y; Tamura T
    Lung Cancer; 2017 Feb; 104():111-118. PubMed ID: 28212992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
    Brahmer J; Reckamp KL; Baas P; Crinò L; Eberhardt WE; Poddubskaya E; Antonia S; Pluzanski A; Vokes EE; Holgado E; Waterhouse D; Ready N; Gainor J; Arén Frontera O; Havel L; Steins M; Garassino MC; Aerts JG; Domine M; Paz-Ares L; Reck M; Baudelet C; Harbison CT; Lestini B; Spigel DR
    N Engl J Med; 2015 Jul; 373(2):123-35. PubMed ID: 26028407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
    Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
    Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.
    Horinouchi H; Nishio M; Hida T; Nakagawa K; Sakai H; Nogami N; Atagi S; Takahashi T; Saka H; Takenoyama M; Katakami N; Tanaka H; Takeda K; Satouchi M; Isobe H; Maemondo M; Goto K; Hirashima T; Minato K; Sumiyoshi N; Tamura T
    Cancer Med; 2019 Sep; 8(11):5183-5193. PubMed ID: 31353840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence.
    Lim JS; Soo RA
    Ther Adv Respir Dis; 2016 Oct; 10(5):444-54. PubMed ID: 27480166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
    Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington K; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Iglesias Docampo LC; Haddad R; Rordorf T; Kiyota N; Tahara M; Monga M; Lynch M; Geese WJ; Kopit J; Shaw JW; Gillison ML
    N Engl J Med; 2016 Nov; 375(19):1856-1867. PubMed ID: 27718784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study.
    Kanda S; Goto K; Shiraishi H; Kubo E; Tanaka A; Utsumi H; Sunami K; Kitazono S; Mizugaki H; Horinouchi H; Fujiwara Y; Nokihara H; Yamamoto N; Hozumi H; Tamura T
    Ann Oncol; 2016 Dec; 27(12):2242-2250. PubMed ID: 27765756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
    Wang J; Lu S; Yu X; Hu Y; Sun Y; Wang Z; Zhao J; Yu Y; Hu C; Yang K; Feng G; Ying K; Zhuang W; Zhou J; Wu J; Leaw SJ; Zhang J; Lin X; Liang L; Yang N
    JAMA Oncol; 2021 May; 7(5):709-717. PubMed ID: 33792623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes of African American patients with advanced or metastatic non-small cell lung cancer on Nivolumab in a single community-based cancer center.
    Tiu AC; Potdar R; Djibo DA; Masab M; Dourado C
    Med Oncol; 2018 Jun; 35(7):109. PubMed ID: 29915891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
    Gettinger SN; Horn L; Gandhi L; Spigel DR; Antonia SJ; Rizvi NA; Powderly JD; Heist RS; Carvajal RD; Jackman DM; Sequist LV; Smith DC; Leming P; Carbone DP; Pinder-Schenck MC; Topalian SL; Hodi FS; Sosman JA; Sznol M; McDermott DF; Pardoll DM; Sankar V; Ahlers CM; Salvati M; Wigginton JM; Hellmann MD; Kollia GD; Gupta AK; Brahmer JR
    J Clin Oncol; 2015 Jun; 33(18):2004-12. PubMed ID: 25897158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nivolumab: a review in advanced squamous non-small cell lung cancer.
    Keating GM
    Drugs; 2015 Nov; 75(16):1925-34. PubMed ID: 26514815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Nivolumab in Previously Treated Patients With Non-Small-cell Lung Cancer: Real World Experience in Argentina.
    Martin C; Lupinacci L; Perazzo F; Bas C; Carranza O; Puparelli C; Kowalyszyn R; Magri I; Varela M; Richardet E; Vera K; Foglia S; Jerez I; Aman E; Martinengo G; Batagelj E; Dri A; Pilnik N; Roa GM; Mando P; Tsou F; Recondo G; Cayol F; Flores M; Sena S; Bagnes C; Waisberg FD; Minatta JN; Rizzo M
    Clin Lung Cancer; 2020 Sep; 21(5):e380-e387. PubMed ID: 32213298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
    Rizvi NA; Hellmann MD; Brahmer JR; Juergens RA; Borghaei H; Gettinger S; Chow LQ; Gerber DE; Laurie SA; Goldman JW; Shepherd FA; Chen AC; Shen Y; Nathan FE; Harbison CT; Antonia S
    J Clin Oncol; 2016 Sep; 34(25):2969-79. PubMed ID: 27354481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    Borghaei H; Paz-Ares L; Horn L; Spigel DR; Steins M; Ready NE; Chow LQ; Vokes EE; Felip E; Holgado E; Barlesi F; Kohlhäufl M; Arrieta O; Burgio MA; Fayette J; Lena H; Poddubskaya E; Gerber DE; Gettinger SN; Rudin CM; Rizvi N; Crinò L; Blumenschein GR; Antonia SJ; Dorange C; Harbison CT; Graf Finckenstein F; Brahmer JR
    N Engl J Med; 2015 Oct; 373(17):1627-39. PubMed ID: 26412456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.